RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology workflows Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality MINNEAPOLIS , Sept. 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of... Read More

Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions MINNEAPOLIS , Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet. "As a... Read More

ST. PAUL, Minn. , Sept. 9, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight (8) G-Rex Grants, totaling nearly $2 million in support, have been awarded to awardees of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network (INFR5) program. CIRM has developed a unique funding opportunity for... Read More

MINNEAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference September 3, 2025 10:15 AM EDT Baird 2025 Global Healthcare Conference September 9, 2025 9:05 AM EDT Morgan Stanley 23 rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT A live webcast of the presentations can... Read More

ST. PAUL, Minn. , Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex... Read More

MINNEAPOLIS , Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025 . The quarterly dividend will be payable August 29, 2025 , to all common shareholders of record on August 18, 2025 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

MINNEAPOLIS , Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025 . Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million . Full year organic revenue increased 5% (5% reported) to $1.2 billion . GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago. Delivered... Read More

MINNEAPOLIS , Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar.... Read More

ST. PAUL, Minn. , Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar , has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex... Read More

ST. PAUL, Minn. , July 31, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that three investigators at the University of Minnesota's Center for Genome Engineering have been awarded $665,000 of G-Rex® Grant funding. Dr. Branden Moriarity , Associate Professor at the University of Minnesota , Co-Director of Center for Genome... Read More

MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025 , at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international... Read More

WOBURN, Mass. / Jul 15, 2025 / Business Wire / Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access... Read More

MINNEAPOLIS , July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease... Read More

MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics ® (NASDAQ: ABEO). Throughout clinical development, Simple... Read More

MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More... Read More

ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India . "The blood cancer burden on India's population is substantial, around... Read More

MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45 th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46 th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of the presentations can be... Read More

ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California ( USC ) and the Children's Hospital of Los Angeles (CHLA). The funding totaling $1,025,000 will support the translation of various cell and gene... Read More

MINNEAPOLIS , May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13 th – 17 th at the New Orleans Ernest N. Morial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell... Read More

Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect ® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes. The companies' combined... Read More

MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 , at 10:40 a.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30 , 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne also announced... Read More

MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025 . Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million . GAAP earnings per share (EPS) was $0.14 versus $0.31 one year ago. Delivered adjusted EPS of $0.56 compared to $0.48 one year ago. Improved pharma end... Read More

ST. PAUL, Minn. , May 6, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf , Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ("A2") has been awarded a $300,000 G-Rex® Grant. A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and will enable A2 to evaluate G-Rex for manufacturing cell therapies. "We are very... Read More

ST. PAUL, Minn. , April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investigational autologous CAR-T cell therapy targeting CD5 for patients with T-cell... Read More

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS , April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity.... Read More

MINNEAPOLIS , April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational... Read More

MINNEAPOLIS , April 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025 , at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 7, 2025 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on... Read More

MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe , Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration... Read More

MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology... Read More

MINNEAPOLIS , March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers... Read More

AmplideX ® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes. MINNEAPOLIS and OXFORD, England , March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX ® Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening... Read More

MINNEAPOLIS , Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45 th Annual Health Care Conference March 4, 2025 2:30 PM EST Leerink Partners Global Healthcare Conference March 11, 2025 11:20 AM EDT Barclays 27 th Annual Global Healthcare Conference March 12, 2025 10:00 AM EDT A live webcast of the presentations can be... Read More

MINNEAPOLIS , Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the... Read More

MINNEAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce... Read More

MINNEAPOLIS , Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024 . Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million . GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago. Improving... Read More

MINNEAPOLIS , Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024 . The quarterly dividend will be payable February 28, 2025 , to all common shareholders of record on February 17, 2025 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

MINNEAPOLIS , Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr , Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025 . Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley . Dr.... Read More

ST. PAUL, Minn. , Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma... Read More

MINNEAPOLIS , Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025 , at 8:00 a.m. CST to review its second quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 5, 2025 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international... Read More

MINNEAPOLIS , Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable... Read More

ST. PAUL, Minn. , Jan. 8, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation , today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant. The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform. "This... Read More

MINNEAPOLIS , Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week , taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas . Bio-Techne will feature... Read More

MINNEAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and... Read More

MINNEAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 10:30 a.m. PST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's... Read More

ST. PAUL, Minn. , Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors. "We are grateful to receive a G-Rex Grant... Read More

MINNEAPOLIS , Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen... Read More

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium MINNEAPOLIS , Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of... Read More

MINNEAPOLIS , Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024 , at 3:15 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

WEST SACRAMENTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida -based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH). GeminiBio... Read More

MINNEAPOLIS , Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which... Read More

MINNEAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella ™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human... Read More

Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS , Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia . Asuragen,... Read More

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology... Read More

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the... Read More

MINNEAPOLIS , Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of... Read More

ST. PAUL, Minn. , Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT). Dr. Ann Leen , a Professor in the Department of Pediatrics at BCM's CAGT, received a $275,000 G-Rex Grant for... Read More

MINNEAPOLIS , Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024 , in Houston, Texas . Bio-Techne's spatial biology brands, Advanced Cell... Read More

MINNEAPOLIS , Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community. COMET, a best-in-class spatial biology... Read More

MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024 . First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million . GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued... Read More

MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024 . The quarterly dividend will be payable November 22, 2024 , to all common shareholders of record on November 11, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis.... Read More

ST. PAUL, Minn. , Oct. 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), today announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. Luminary's G-Rex® Grant will enable expeditious process development and IND-enabling studies of several novel CAR γδ T cell therapies that will be evaluated in Phase 1 clinical trials for the... Read More

MINNEAPOLIS , Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024 , at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 30, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform ST. PAUL, Minn. , Oct. 9, 2024 /PRNewswire/ -- ScaleReady ™ , in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady ™ , and LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its... Read More

ST. PAUL, Minn. , Oct. 8, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Eric Tran , Ph.D, Associate Member of the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, has been awarded a G-Rex Grant. Dr. Tran's $200,000 G-Rex Grant will enable process development and IND enabling... Read More

ST. PAUL, Minn. , Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A. Klebanoff , MD, a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) has been awarded a G-Rex ® Grant. Dr. Klebanoff's $300,000 G-Rex ® Grant will provide enabling reagents to facilitate process development,... Read More

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore , is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™ , a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research. The strategic partnership... Read More

MINNEAPOLIS , Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024 , in Chicago, Illinois . At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science... Read More

MINNEAPOLIS , Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values... Read More

ST. PAUL, Minn. , Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex ® Grant. ImmunoScape's $250,000 G-Rex ® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell... Read More

ST. PAUL, Minn. , Sept. 17, 2024 /PRNewswire/ -- ScaleReady TM , in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady TM , today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics , a clinical-stage CAR T company developing the novel KIR-CAR platform technology. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development... Read More

PHILADELPHIA , Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics , a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20... Read More

ST. PAUL, Minn. , Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPak TM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing. The ProPak TM GMP Cytokine product consists of a weldable bag filled with liquid formulated GMP-grade cytokines, specifically interleukin-7... Read More

ST. PAUL, Minn. , Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman , Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of... Read More

MINNEAPOLIS , Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT 2024 Wells Fargo Healthcare Conference September 6, 2024 11:00 AM EDT Baird 2024 Global Healthcare Conference September 10, 2024... Read More

MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024 . The quarterly dividend will be payable August 30, 2024 , to all common shareholders of record on August 19, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024 . Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million . Full year organic revenue increased 1% (2% reported) to $1.2 billion . GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered... Read More

MINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems. This state-of-the-art instrument enables simultaneous processing of up to 100 samples in a single 3-hour run, allowing scientists to... Read More

MINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in... Read More

MINNEAPOLIS , July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation ( NASDAQ : TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024 , at 8:00 a.m . CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 7, 2024 Dial-in: 1-800-343-4136 or 1-203-518-9843 (for international callers)... Read More

MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following investor conferences: William Blair 44 th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45 th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A... Read More

MINNEAPOLIS , May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72 nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd -6 th in Anaheim, California . The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation... Read More

ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT). The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research,... Read More

MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 , at 8:40 a.m. CDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose)... Read More

MINNEAPOLIS , May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024 , at 2:20 p.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar... Read More

MINNEAPOLIS , May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024 , in Baltimore, Maryland . Bio-Techne's booth (#1627 ) will feature our market-leading portfolio of high-quality life science research use... Read More

MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024 . Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million . GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. Strong commercial... Read More

MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024 . The quarterly dividend will be payable May 24, 2024 , to all common shareholders of record on May 13, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation... Read More

MINNEAPOLIS , April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024 . Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are... Read More

MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024 , Bio-Techne will enter into a strategic distribution agreement with... Read More

MINNEAPOLIS , April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP), a first of its kind ocular biomarker kit, as a point-of-care application. Novomol-Dx is a molecular diagnostics company focused on commercializing tests for the diagnosis and treatment of ophthalmic diseases utilizing... Read More

Bio-Techne enforces intellectual property for gold standard RNAscope® ISH technology in spatial biology research and clinical applications. MINNEAPOLIS , April 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent... Read More

MINNEAPOLIS , April 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024 , at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference... Read More

Advanced Cell Diagnostics (ACD) achieves significant global customer adoption milestone MINNEAPOLIS , April 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope ™ ISH technology. Over 50% of these publications were... Read More

MINNEAPOLIS , April 3, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024 , in San Diego, California . Bio-Techne will showcase its solutions at booth #541 , featuring... Read More

MINNEAPOLIS , April 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced that its R&D Systems brand has been named "ELISA Kit Supplier of the Year" in CiteAb's prestigious annual industry awards. Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology... Read More

MINNEAPOLIS , March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers. Lunaphore's flagship COMET technology is the only fully-automated, high-throughput,... Read More

The QuantideX ® qPCR BCR-ABL IS Kit is now compliant with the latest diagnostic regulations in Europe MINNEAPOLIS , March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX ® qPCR BCR-ABL IS Kit. Previously,... Read More

MINNEAPOLIS , March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist , President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024 , at 9:45 a.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , March 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer, will present at the Barclays 26 th Annual Global Healthcare Conference on Wednesday, March 13, 2024 , at 8:30 a.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2023 . Second Quarter FY2024 Highlights Second quarter organic revenue declined by 2% (0% reported) to $272.6 million . Organic revenue remained flat (2% reported) in the first half of fiscal 2024 at $549.5 million . GAAP earnings per share (EPS) was $0.17 versus... Read More

MINNEAPOLIS , Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023 . The quarterly dividend will be payable February 26, 2024 , to all common shareholders of record on February 12, 2024 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology. MINNEAPOLIS , Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD) , a Bio-Techne spatial biology brand, has set a new standard with the... Read More

MINNEAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD) , will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers. This state-of-the-art solution revolutionizes the field of predictive biomarker research and drug development. The... Read More

MINNEAPOLIS , Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in Washington D.C. The focus of these presentations was on the transformative impact of Bio-Techne's MauriceFlex™ system on their biotherapeutic development processes. MauriceFlex™, known... Read More

MINNEAPOLIS , Jan. 16, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 1, 2024 , at 8:00 a.m. CST to review second quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 1, 2024 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

MINNEAPOLIS , Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024 . Dr. McManus succeeds Kim Kelderman , who will become Bio-Techne's Chief Executive Officer effective February 1, 2024 . Dr. McManus has over two decades of experience as a senior life sciences leader, most recently... Read More

MINNEAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to enable cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week , taking place January 16-19 at the Miami Beach Convention Center in Miami, Florida . Bio-Techne's booth (#509) will feature its wide range of products, services, and... Read More

MINNEAPOLIS , Dec. 21, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024 , will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 , at 9:00 a.m. PST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor... Read More

MINNEAPOLIS , Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free ( CCM0036-GMP ), supporting the development and manufacture of regenerative medicine and stem cell therapies. ExCellerate GMP iPSC Expansion Medium is optimized to support robust... Read More

MINNEAPOLIS , Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics , have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential... Read More

MINNEAPOLIS , Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, and Kim Kelderman , Chief Operating Officer will present at the 6 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 , at 2:10 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor... Read More

MINNEAPOLIS , Nov. 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: Stifel 2023 Healthcare Conference November 15, 2023 8:35 AM EST Stephens Annual Investment Conference November 15, 2023 3:00 PM EST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving... Read More

MINNEAPOLIS , Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2023 . First Quarter FY2024 Highlights First quarter organic revenue increased by 2% (3% reported) to $276.9 million . GAAP earnings per share 1) (EPS) was $0.31 versus $0.55 one year ago. Delivered adjusted EPS 1) of $0.41 compared to $0.45 one year ago. Our ExoDx... Read More

MINNEAPOLIS , Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2023 . The quarterly dividend will be payable November 24, 2023 , to all common shareholders of record on November 10, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis.... Read More

MINNEAPOLIS and LAUSANNE, Switzerland , Oct. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting , taking place in San Diego , November 1-5, 2023 . The recent studies will demonstrate the unmatched... Read More

MINNEAPOLIS , Oct. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Board of Directors appointed Kim Kelderman as President and Chief Executive Officer effective February 1, 2024 . Concurrent with his role as CEO, Mr. Kelderman will also become a member of Bio-Techne's Board of Directors. Prior to assuming CEO responsibilities, Mr. Kelderman will become Chief Operating Officer (COO)... Read More

MINNEAPOLIS , Oct. 16, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and Immunoassays today announced that its Wallingford, CT facility has received ISO 13485:2023 certification for its quality management system (QMS), demonstrating the company's commitment to producing products for clinical applications. The company's Wallingford site manufacturers Bio-Techne's... Read More

MINNEAPOLIS , Oct. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, October 31, 2023 , at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: October 31, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers)... Read More

MINNEAPOLIS , Sept. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Jordan Laser has received the AMP Meritorious Service Award from the Association for Molecular Pathology (AMP). Dr. Laser is receiving this honor to recognize his dedication and effort behind the scenes to position AMP as the premier molecular diagnostics professional association around the world. Dr. Laser currently... Read More

MINNEAPOLIS , Sept. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighted how Bio-Techne's ProteinSimple branded Maurice™ and MauriceFlex™ systems improved their therapeutic development workflows. Both systems offer automated capillary isoelectric focusing... Read More

MINNEAPOLIS , Sept. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to launch the new Maurice Chromeleon Driver Kit, which enables control of its Maurice™ instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System (CDS). In addition to Compass for iCE, and Waters™ Empower® CDS, scientists now can use Chromeleon CDS to analyze protein charge and size data generated from the Maurice... Read More

MINNEAPOLIS , Sept. 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2023 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values... Read More

LONDON and MINNEAPOLIS , Sept. 19, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc, the UK-based diagnostics developer, are pleased to announce recent progress evaluating specific monoclonal antibodies for Cizzle's CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from... Read More

MINNEAPOLIS , Aug. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor healthcare conferences: 2023 Wells Fargo Healthcare Conference September 6, 2023 10:15 AM EDT Baird 2023 Global Healthcare Conference September 12, 2023 4:55 PM EDT Morgan Stanley 21 st Annual Global Healthcare Conference September 13, 2023 2:55 PM EDT A live webcast of the... Read More

MINNEAPOLIS , Aug. 24, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2023 Investor Day on Friday, September 8, 2023 , starting at 8:30 a.m. EDT . The meeting will take place at the JW Marriott Essex House New York, 160 Central Park South, New York City . The Investor Day will feature presentations from members of Bio-Techne's senior leadership team followed by Q&A.... Read More

MINNEAPOLIS , Aug. 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the UBS MedTech, Tools and Genomics Summit 2023 on Thursday, August 17, 2023 , at 10:00 a.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The decision was made following best efforts... Read More

MINNEAPOLIS , Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ended June 30, 2023 . Fourth Quarter FY2023 Highlights Fourth quarter organic revenue increased by 5% (5% reported) to $301.3 million . Full year organic revenue increased 5% (3% reported) to $1.1 billion . GAAP earnings per share 1) (EPS) was $0.47 versus $0.38 one year ago. Delivered... Read More

MINNEAPOLIS , Aug. 8, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2023 . The quarterly dividend will be payable September 1, 2023 , to all common shareholders of record on August 18, 2023.... Read More

MINNEAPOLIS , July 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, August 8, 2023 , at 8:00 a.m. CDT to review fourth quarter and fiscal 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 8, 2023 Dial-in: 1-877-300-8521 or 1-412-317-6026 (for international callers)... Read More

MINNEAPOLIS , July 10, 2023 /PRNewswire/ -- Bio-Techne Pharmaceutical (NASDAQ:TECH) today announced it has completed the acquisition of Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. Bio-Techne and Lunaphore are combining forces to accelerate their spatial biology leadership position in translational and clinical research markets. Lunaphore's instrument portfolio includes COMET ™... Read More

TOLOCHENAZ, Switzerland & MINNEAPOLIS / Jun 22, 2023 / Business Wire / L unaphore Technologies SA , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic... Read More

MINNEAPOLIS and TOLOCHENAZ, Switzerland , June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Lunaphore, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its fiscal 2024. Founded in 2014 and... Read More

MINNEAPOLIS , June 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies. Specifically, the Court held "it has been proven that [Miltenyi's] TIGIT and CCR-7 antibodies are the... Read More

MINNEAPOLIS , May 25, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023 , at 12:30 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS , May 18, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients aimed at evaluating the... Read More

Enabling Bio-Techne's gold-standard RNAscope ISH technology with Imaging Mass Cytometry detection to accelerate multiomic interrogation of health and disease. MINNEAPOLIS , May 16, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the expansion of the Advanced Cell Diagnostics... Read More

MINNEAPOLIS , May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 , at 2:35 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , May 10, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells. Detection... Read More

MINNEAPOLIS , May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ended March 31, 2023 . Third Quarter FY2023 Highlights Third quarter organic revenue increased by 3% (1% reported) to $294.1 million and 4% (2% reported) in the first nine months of fiscal 2023 to $835.4 million . GAAP earnings per share 1) (EPS) was $0.43 versus $0.37 one year ago.... Read More

MINNEAPOLIS , May 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2023 . The quarterly dividend will be payable May 26, 2023 , to all common shareholders of record on May 15, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation... Read More

MINNEAPOLIS , May 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 , at 1:40 p.m. PDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Bringing together Bio-Techne's gold standard RNAscope™ technology with Lunaphore's multiplex sequential immunofluorescence (seqIF™) COMET™ system to develop a best-in-class end-to-end multiomics workflow. MINNEAPOLIS and LAUSANNE, Switzerland , April 17, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences... Read More

MINNEAPOLIS , April 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell and gene therapy development and manufacturing at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 14-19 in Orlando, Florida . Bio-Techne's booth (#1763) will feature its wide... Read More

MINNEAPOLIS , April 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 3, 2023 , at 8:00 a.m. CDT to review third quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 3, 2023 Dial-in: 1-877-300-8521 or 1-412-317-6026 (for international callers) Conference ID:... Read More

MINNEAPOLIS , April 5, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field. The achievement is a testament to the growing demand across scientific and clinical research sectors for a fast and efficient immunoassay solution capable of delivering precise, and reliable biomarker... Read More

MINNEAPOLIS , April 3, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its investment in Wilson Wolf Manufacturing. Wilson Wolf achieved the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million , triggering Bio-Techne's initial investment in the company. Bio-Techne's $257 million investment gives the Company a 20%... Read More

MINNEAPOLIS , March 15, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional... Read More

MINNEAPOLIS , March 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023 , at 2:35 p.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , March 1, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target of $55 million , triggering Bio-Techne's initial investment in the company, which is expected to close at the end of March 2023 . Bio-Techne's $257 million investment will give the Company a 20%... Read More

MINNEAPOLIS , Feb. 28, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023 , at 2:10 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing MINNEAPOLIS , Feb. 24, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that a newly finalized local coverage determination (LCD) from National Government Services, Inc., a Medicare Administrative Contractor, includes... Read More

MINNEAPOLIS , Feb. 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 , at 2:00 p.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Feb. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Cell Signaling Technology (CST) announced today the addition of Simple Western™ validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform. Obtaining accurate data efficiently and fast is key to advancing drug discovery... Read More

MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2022 . Second Quarter FY2023 Highlights Second quarter organic revenue increased by 4% (1% reported) to $271.6 million and 5% (3% reported) in the first half of fiscal 2023 to $541.2 million . GAAP earnings per share 1) (EPS) was $0.31 versus $0.49 one year ago.... Read More

MINNEAPOLIS , Feb. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2022 . The quarterly dividend will be payable February 27, 2023 , to all common shareholders of record on February 13, 2023 . Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne... Read More

MINNEAPOLIS , Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3 , 2023. Mr. Bohnen succeeds Brenda Furlow , who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until... Read More

MINNEAPOLIS , Jan. 26, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D.C. MauriceFlex™ enables protein charge variant fractionation plus routine cIEF & CE-SDS assays, making it a unique multi-functional system that further streamlines protein characterization workflows. In-depth characterization of... Read More

MINNEAPOLIS , Jan. 17, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023 , at 8:00 a.m. CST to review second quarter 2023 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 2, 2023 Dial-in: 1-877-407-9208 or 1-201-493-6784 (for international callers) Conference... Read More

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. MINNEAPOLIS , Jan. 10, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of the RNAscope Plus... Read More

MINNEAPOLIS , Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 , at 8:15 a.m. PST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More

MINNEAPOLIS , Dec. 5, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant ™ probes. These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells. Fluorescent probes that enable highly accurate, sensitive, specific and persistent labeling of mitochondria is critical for a range of demanding scientific and biomedical... Read More

New collaboration will develop assays that offer a streamlined workflow for analysing even the most challenging genes. MINNEAPOLIS , Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc ( Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.... Read More

MINNEAPOLIS , Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022 , at 8:50 a.m. EST . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at... Read More